# 公眾即將首次看到自川普總統與17家藥廠達成最惠國待遇協議後所推出藥物的價格。

*biotech · news · 2026-05-28 · STAT*

## Key points

- 三款即將上市的藥物將揭示川普最惠國價格協議如何影響美國藥價。
- 這些協議要求美國新藥上市價格與其他富裕國家相符。
- 相關藥物分別是來自阿斯利康、諾和諾德及Arvinas/Pfizer的Baxfendy、Awiqli和Veppanu。
- Baxfendy和Veppanu目前在其他富裕國家尚無可供價格比較的上市情況。

Top of the morning to you. And a fine one it is here at the Pharmalot campus, where the official mascots are quietly snoozing now that our shortest person has returned to her out-of-town studies. As for us, we are downing another cup of stimulation — blueberry cobbler is our preference today. Feel free to join us. As always, here are your tidbits. Hope your day goes well and you conquer the world. And of course, do stay in touch. … The public is about to get its first look at the prices of drugs launched since President Trump struck his most-favored-nation deals with 17 drugmakers, STAT tells us. Those deals require companies to launch new drugs in the U.S. at net prices roughly equal to those in other wealthy nations, though precise terms are secret. Three medicines that are set to launch in the coming months will provide the most public view yet of the practical impacts of Trump’s dealmaking. The drugs are Baxfendy for hypertension from AstraZeneca, the insulin Awiqli from Novo Nordisk, and Veppanu, a cancer drug developed by Arvinas and Pfizer that is set to be licensed to Rigel Pharmaceuticals. Baxfendy and Veppanu are not yet available in other wealthy countries that are used as comparisons for reference pricing. Advertisement

**Companies:** Arvinas, Rigel Pharmaceuticals
**Countries:** United States

[Read the full story on STAT](https://www.statnews.com/pharmalot/2026/05/28/hepatitis-drug-cvs-returns-lilly-obesity-drug-to-formularies/)

---

Canonical: https://newsio.io/zh-TW/n/7fb9c2c5-d41d-4869-a426-545746f7869a/17
Summarized by Newsio from STAT. https://newsio.io/how-it-works